US 10111878
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
granted A61KA61K31/53A61K45/06
Quick answer
US patent 10111878 (N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer) held by Agios Pharmaceuticals, Inc. expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Agios Pharmaceuticals, Inc.
- Grant date
- Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/53, A61K45/06, A61P, A61P35/00